330 related articles for article (PubMed ID: 35984598)
1. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
Waksal JA; Mascarenhas J
Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutics and targets in myelofibrosis.
Waksal JA; Harrison CN; Mascarenhas JO
Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
[TBL] [Abstract][Full Text] [Related]
3. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
4. New Treatments for Myelofibrosis.
Tremblay D; Mesa R
Curr Treat Options Oncol; 2023 Feb; 24(2):61-75. PubMed ID: 36640223
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
6. Novel treatments for myelofibrosis: beyond JAK inhibitors.
Tremblay D; Mesa R
Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
8. State-of-the-Art Review on Myelofibrosis Therapies.
Wang F; Qiu T; Wang H; Yang Q
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
Tremblay D; Hoffman R
Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
[TBL] [Abstract][Full Text] [Related]
10. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
11. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
12. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
13. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
[TBL] [Abstract][Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Fedratinib in Myelofibrosis.
Waksal JA; Tremblay D; Mascarenhas J
Onco Targets Ther; 2021; 14():4509-4521. PubMed ID: 34456572
[TBL] [Abstract][Full Text] [Related]
16. Recent progress of JAK inhibitors for hematological disorders.
Kirito K
Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anemia in myelofibrosis: focusing on novel therapeutic options.
Arslan Davulcu E; Oğuz MB; Kılıç E; Eşkazan AE
Expert Opin Investig Drugs; 2024 Jan; 33(1):27-37. PubMed ID: 38073183
[TBL] [Abstract][Full Text] [Related]
18. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
Duminuco A; Vetro C; Giallongo C; Palumbo GA
Expert Opin Pharmacother; 2023; 24(13):1449-1461. PubMed ID: 37341682
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of Myelofibrosis.
Tremblay D; Marcellino B; Mascarenhas J
Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
[TBL] [Abstract][Full Text] [Related]
20. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
Morsia E; Gangat N
Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
[No Abstract] [Full Text] [Related]
[Next] [New Search]